Innovative sequential therapy in a rare case of refractory Erdheim-Chester disease with bilateral pulmonary involvement [0.03%]
复发性难治性Erdheim-Chester病伴双肺受累的创新序贯疗法在一例罕见病例中的应用
Zengyan Li,Zhiming Wu,Zelin Zhang et al.
Zengyan Li et al.
Background: Erdheim-Chester Disease (ECD) is a rare, multisystemic histiocytosis with complex diagnosis and management. Case Presentation: We report a case of a 44-year-old male with ECD,confirmed by lung biopsy, presenting with persistent ...
Initial cumulative area under the blood concentration-time curve of vancomycin is associated with the incidence of acute kidney injury [0.03%]
万古霉素早期累计曲线下面积与急性肾损伤发生率相关性研究
Yuta Ibe,Tomoyuki Ishigo,Satoshi Fujii et al.
Yuta Ibe et al.
We aimed to evaluate the relationship between the cumulative area under the concentration-time curve (AUC) for the first and second day of vancomycin (VCM) administration and acute kidney injury (AKI). The primary outcome was the cumulative...
E2F1-induced transcriptional activation of MAL2 inhibits sunitinib sensitivity and promotes the malignant progression of bladder cancer [0.03%]
E2F1诱导的MAL2转录激活抑制索拉非尼敏感性并促进膀胱癌恶性进展
Mingqiang Su,Wei Chen,Jingxian Luo et al.
Mingqiang Su et al.
Background: Mal, T cell differentiation protein 2 (MAL2) has emerged as a potential regulator in the progression of bladder cancer (BCa). Therapeutic resistance to sunitinib poses a significant challenge in BCa treatment....
Clinical features, treatments, and outcomes of atezolizumab-induced diabetes mellitus in cancer patients [0.03%]
阿特珠单抗致糖尿病的临床特征、治疗及转归-1例报告
Jian Xiao,Zhi Xia,Zhu Wu et al.
Jian Xiao et al.
To explore the clinical characteristics of diabetes mellitus (DM) induced by atezolizumab in cancer patients and provide evidence to guide the rational clinical application of atezolizumab. We conducted a retrospective study on diabetes ind...
Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024 [0.03%]
基于FAERS的药物警戒研究（2013-2024）：与免疫检查点抑制剂阿维鲁单抗相关的肺部不良事件特征分析
Connor Frey
Connor Frey
The rise of immunotherapies, particularly PD-L1 inhibitors like avelumab, has advanced cancer care, but its pulmonary safety profile remains unclear. Using FAERS data from 2013-2023, we evaluated respiratory complications linked to avelumab...
DNMT1 reduces cisplatin sensitivity partially through downregulating FOXO3a in ovarian cancer cells [0.03%]
DNA甲基转移酶1通过降低FOXO3a蛋白表达部分介导卵巢癌细胞对顺铂耐药性
Chong Guo,Qingqing Yu,Fangzhou Li et al.
Chong Guo et al.
Most individuals with ovarian cancer (OC) develop cisplatin resistance while undergoing treatment. Bioinformatic analysis has linked DNA Methyltransferase 1 (DNMT1) to chemoresistance development as well as FOXO3a expression in OC patients....
Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG) [0.03%]
帕博西尼治疗脂肪肉瘤的疗效和安全性——来自土耳其肿瘤协会（TOG）的真实世界多中心数据
Fatih Kus,Hasan Cagri Yildirim,Dogan Bayram et al.
Fatih Kus et al.
Background: Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trial...
Combination therapy does not decrease 30-day mortality but increases antibiotic consumption in methicillin-sensitive S. aureus bacteraemia [0.03%]
联合疗法不会降低金黄色葡萄球菌败血症30天的死亡率，但会增加抗生素的使用量
Özge Özgen-Top,Pınar Aysert-Yildiz,Hamid Habibi et al.
Özge Özgen-Top et al.
Purpose: The study aimed to compare the impact of combination and monotherapy on mortality, antibiotic consumption using 'Days of Therapy (DOT)', and antibiotic-related adverse events in patients with methicillin-suscepti...
A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancer [0.03%]
阿贝西利联合阿比特龙治疗日本转移性去势抵抗性前列腺癌患者I期研究
Nobuaki Matsubara,Koji Dozono,Karim Nacerddine et al.
Nobuaki Matsubara et al.
The aim of this Phase 1, multicentre, open-label study was to evaluate the safety, tolerability and pharmacokinetics (PK) of abemaciclib administered at global recommended Phase 2 dose (RP2D) of 200 mg twice daily, combined with standard do...
Influencing factors of acute severe to very severe peripheral neuropathy induced by albumin-bound paclitaxel [0.03%]
影响白蛋白结合型紫杉醇所致急性重度外周神经病变的因素分析
Yi Huang,Lijuan Feng,Jing Hu et al.
Yi Huang et al.
Paclitaxel is the primary chemotherapy agents for many high-incidence cancers, and they also pose a significant risk for peripheral neuropathy. This study investigated the factors influencing paclitaxel-induced peripheral neuropathy (PIPN)....